Consumer health worldwide operational sales of $3.29 billion, excluding the net impact of acquisitions and divestitures, increased 10.0% inclusive of the market recovery from COVID-19 impacts, primarily in skin health/beauty. Sales growth was driven by skin health/beauty products including Neutrogena, Aveeno, and OGX as well as by J&J’s over-the-counter products ( upper respiratory products, international analgesics and digestive health products) and its iconic Band-Aid bandages.
"Our second-quarter results showcase Johnson & Johnson's diversified portfolio, driven by strong sales and earnings growth across our medical device, consumer health and pharmaceutical businesses," said Alex Gorsky, chairman and CEO. "I'm so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulatory submissions. These accomplishments exemplify our commitment to advancing transformational innovations that improve the health of people and communities everywhere while continuing to deliver long-term value to all of our stakeholders."